Human Chronic Lymphoid Leukemia Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

Description

Human Chronic Lymphoid Leukemia Peripheral Blood Mononuclear Cells (CLL PBMCs) (Relapsed/Refractory) are primary cells isolated from CLL patients who have failed multiple lines of therapy, representing a critical resource for studying drug resistance and aggressive disease biology. These PBMCs contain treatment-evolved malignant B-cells (CD5⁺/CD19⁺/CD23⁺) with acquired resistance mechanisms such as BTK/PLCG2 mutations (for ibrutinib resistance), BCL-2 mutations (for venetoclax resistance), or complex karyotypic abnormalities. In advanced translational studies, these specimens are instrumental for dissecting cell signaling relapsed leukemia, profiling PBMC gene expression relapsed CLL, accelerating novel therapies in refractory leukemia, advancing refractory chronic lymphoid research, evaluating CLL disease progression, enabling relapsed leukemia monitoring, and supporting comprehensive human relapsed leukemia study programs.

Application

• Human Chronic Lymphocytic Leukemia Peripheral Blood Mononuclear Cells (Relapsed/Refractory) provide an ideal model for exploring the mechanism of chronic lymphocytic leukemia (CLL) resistance: acquired mutations (e.g., BTK C481S and PLCG2 mutations) can be analyzed through genome sequencing, and BCR signaling pathway reconstruction (e.g., reduced microenvironment dependence caused by CXCR4 downregulation) can be studied.